FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2643-2653 December 22, 2005 Number 25 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Cefalu, W. T. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Intensive diabetes therapy aimed at achieving near normoglycemia reduces the risk of microvascular and neurologic complications of type 1 diabetes. We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease.

Methods The DCCT randomly assigned 1441 patients with type 1 diabetes to intensive or conventional therapy, treating them for a mean of 6.5 years between 1983 and 1993. Ninety-three percent were subsequently followed until February 1, 2005, during the observational Epidemiology of Diabetes Interventions and Complications study. Cardiovascular disease (defined as nonfatal myocardial infarction, stroke, death from cardiovascular disease, confirmed angina, or the need for coronary-artery revascularization) was assessed with standardized measures and classified by an independent committee.

Results During the mean 17 years of follow-up, 46 cardiovascular disease events occurred in 31 patients who had received intensive treatment in the DCCT, as compared with 98 events in 52 patients who had received conventional treatment. Intensive treatment reduced the risk of any cardiovascular disease event by 42 percent (95 percent confidence interval, 9 to 63 percent; P=0.02) and the risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57 percent (95 percent confidence interval, 12 to 79 percent; P=0.02). The decrease in glycosylated hemoglobin values during the DCCT was significantly associated with most of the positive effects of intensive treatment on the risk of cardiovascular disease. Microalbuminuria and albuminuria were associated with a significant increase in the risk of cardiovascular disease, but differences between treatment groups remained significant (P0.05) after adjusting for these factors.

Conclusions Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes.

Source Information

The Writing Committee — David M. Nathan, M.D. (chair), Patricia A. Cleary, M.S., Jye-Yu C. Backlund, M.S., Saul M. Genuth, M.D., John M. Lachin, D.Sc., Trevor J. Orchard, M.D., Philip Raskin, M.D., and Bernard Zinman, M.D. — vouches for the accuracy and integrity of the data.

Address reprint requests to the DCCT/EDIC Research Group at Box NDIC/DCCT, Bethesda, MD 20892, or at dnathan{at}partners.org.

Full Text of this Article

Related Letters:

Intensive Diabetes Treatment and Cardiovascular Disease
Weissman A. J., Ross P. S., Nathan D. M., Genuth S., Lachin J., Cefalu W. T.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1751-1752, Apr 20, 2006. Correspondence

This article has been cited by other articles:

• Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 161: 1-9 [Abstract] [Full Text]  
• Kazempour-Ardebili, S., Lecamwasam, V. L., Dassanyake, T., Frankel, A. H., Tam, F. W.K., Dornhorst, A., Frost, G., Turner, J. J.O. (2009). Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care 32: 1137-1142 [Abstract] [Full Text]  
• Groop, P.-H., Thomas, M. C., Moran, J. L., Waden, J., Thorn, L. M., Makinen, V.-P., Rosengard-Barlund, M., Saraheimo, M., Hietala, K., Heikkila, O., Forsblom, C., on behalf of the FinnDiane Study Group, (2009). The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes. Diabetes 58: 1651-1658 [Abstract] [Full Text]  
• Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E. (2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol 53: 2129-2140 [Abstract] [Full Text]  
• Chaturvedi, N. (2009). Metabolic Memory in the Autonomic Neuropathy of Diabetes: Implications for Pathogenesis and Patient Care. Circulation 119: 2865-2867 [Full Text]  
• Pop-Busui, R., Low, P. A., Waberski, B. H., Martin, C. L., Albers, J. W., Feldman, E. L., Sommer, C., Cleary, P. A., Lachin, J. M., Herman, W. H., for the DCCT/EDIC Research Group, (2009). Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation 119: 2886-2893 [Abstract] [Full Text]  
• Clement, M., Bhattacharyya, O., Conway, J. R. (2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp 55: 580-582 [Full Text]  
• Clement, M., Bhattacharyya, O., Conway, J. R. (2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp 55: 584-588 [Full Text]  
• Booth, G. L (2009). Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Evid. Based Med. 14: 73-73 [Full Text]  
• Bloomgarden, Z. T. (2009). Cardiovascular Disease, Neuropathy, and Retinopathy. Diabetes Care 32: e64-e68 [Full Text]  
• Dale, A. C., Midthjell, K., Nilsen, T. I., Wiseth, R., Vatten, L. J. (2009). Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway. Eur Heart J 30: 1372-1377 [Abstract] [Full Text]  
• Bartnik, M., Cosentino, F. (2009). Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. Eur Heart J 30: 1301-1304 [Full Text]  
• Davis, S. M., Donnan, G. A. (2009). Antiplatelet Activity. Stroke 40: 2275-2275 [Full Text]  
• Roy, M. S., Hallman, D. M., Fu, Y.-P., Machado, M., Hanis, C. L. (2009). Assessment of 193 Candidate Genes for Retinopathy in African Americans With Type 1 Diabetes. Arch Ophthalmol 127: 605-612 [Abstract] [Full Text]  
• Nansel, T. R., Iannotti, R. J., Simons-Morton, B. G., Plotnick, L. P., Clark, L. M., Zeitzoff, L. (2009). Long-Term Maintenance of Treatment Outcomes: Diabetes Personal Trainer Intervention for Youth With Type 1 Diabetes. Diabetes Care 32: 807-809 [Abstract] [Full Text]  
• Weiss, A. S., Smits, G., Wiseman, A. C. (2009). Twelve-Month Pancreas Graft Function Significantly Influences Survival Following Simultaneous Pancreas-Kidney Transplantation. CJASN 4: 988-995 [Abstract] [Full Text]  
• Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., El-Osta, A. (2009). Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes 58: 1229-1236 [Abstract] [Full Text]  
• Cheng, A. Y.Y., Leiter, L. A. (2009). Cardiovascular risk and glycemic control. CMAJ 180: 907-908 [Full Text]  
• Ko, G. T.C., So, W.-Y., Tong, P. C., Chan, W.-B., Yang, X., Ma, R. C., Kong, A. P., Ozaki, R., Yeung, C.-Y., Chow, C.-C., Chan, J. C. (2009). Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ 180: 919-926 [Abstract] [Full Text]  
• Kahn, S. E. (2009). Glucose Control in Type 2 Diabetes: Still Worthwhile and Worth Pursuing. JAMA 301: 1590-1592 [Full Text]  
• Nathan, D. M. (2009). Progress in Diabetes Research--What's Next. JAMA 301: 1599-1601 [Full Text]  
• Cochran, E. (2009). U-500 Insulin: When More With Less Yields Success. Diabetes Spectr. 22: 116-122 [Full Text]  
• Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D. (2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice 22: 179-193 [Abstract]  
• Greene, S. (2009). Diabetes in the young: what are their long term health prospects?. Arch. Dis. Child. 94: 251-253 [Full Text]  
• Chait, A., Bornfeldt, K. E. (2009). Diabetes and atherosclerosis: is there a role for hyperglycemia?. J. Lipid Res. 50: S335-S339 [Abstract] [Full Text]  
• Campbell, I. W (2009). Review: Durable glycaemia -- the promised land. British Journal of Diabetes & Vascular Disease 9: 53-63 [Abstract]  
• Niswender, K. (2009). Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?. Clin. Diabetes 27: 60-68 [Abstract] [Full Text]  
• Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., Service, F. J. (2009). Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 94: 709-728 [Abstract] [Full Text]  
• Amiel, S. A., Cryer, P. E. (2009). Attenuated Sympathoadrenal Responses, but Not Severe Hypoglycemia, During Aggressive Glycemic Therapy of Early Type 2 Diabetes. Diabetes 58: 515-517 [Full Text]  
• Garg, S. K., Voelmle, M. K., Gottlieb, P. (2009). Feasibility of 10-Day Use of a Continuous Glucose-Monitoring System in Adults With Type 1 Diabetes. Diabetes Care 32: 436-438 [Abstract] [Full Text]  
• Engberding, N., San Martin, A., Martin-Garrido, A., Koga, M., Pounkova, L., Lyons, E., Lassegue, B., Griendling, K. K. (2009). Insulin-Like Growth Factor-1 Receptor Expression Masks the Antiinflammatory and Glucose Uptake Capacity of Insulin in Vascular Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Bio. 29: 408-415 [Abstract] [Full Text]  
• Siebenhofer-Kroitzsch, A. MD, Horvath, K. MD, Plank, J. MD (2009). Insulin analogues: too much noise about small benefits. CMAJ 180: 369-370 [Full Text]  
• Cameron, C. G. MSc, Bennett, H. A. BPharm PhD (2009). Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 180: 400-407 [Abstract] [Full Text]  
• Dandona, P., Chaudhuri, A., Ghanim, H., Mohanty, P. (2009). Insulin as an anti-inflammatory and antiatherogenic modulator.. J Am Coll Cardiol 53: S14-S20 [Abstract] [Full Text]  
• Orasanu, G., Plutzky, J. (2009). The pathologic continuum of diabetic vascular disease.. J Am Coll Cardiol 53: S35-S42 [Abstract] [Full Text]  
• O'Sullivan, E. P, Dinneen, S. F (2009). Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years. Evid. Based Med. 14: 9-10 [Full Text]  
• Ceriello, A., Ihnat, M. A., Thorpe, J. E. (2009). The "Metabolic Memory": Is More Than Just Tight Glucose Control Necessary to Prevent Diabetic Complications?. J. Clin. Endocrinol. Metab. 94: 410-415 [Abstract] [Full Text]  
• Panero, F., Novelli, G., Zucco, C., Fornengo, P., Perotto, M., Segre, O., Grassi, G., Cavallo-Perin, P., Bruno, G. (2009). Fasting Plasma C-Peptide and Micro- and Macrovascular Complications in a Large Clinic-Based Cohort of Type 1 Diabetic Patients. Diabetes Care 32: 301-305 [Abstract] [Full Text]  
• Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., Freeman, R. (2009). Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function: Implications for Rigorous Glycemic Control. Diabetes 58: 360-366 [Abstract] [Full Text]  
• Havas, S. (2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med 169: 150-154 [Full Text]  
• Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53: 298-304 [Full Text]  
• Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119: 351-357 [Full Text]  
• Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., the VADT Investigators, (2009). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. NEJM 360: 129-139 [Abstract] [Full Text]  
• Grant, P. J (2009). The EASD/ADA consensus: trick or treat?. Diabetes and Vascular Disease Research 6: 5-6  
• Lindsey, J. B, Cipollone, F., Abdullah, S. M, Mcguire, D. K (2009). Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes and Vascular Disease Research 6: 7-14 [Abstract]  
• Gore, M O., McGuire, D. K (2009). The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diabetes and Vascular Disease Research 6: 53-55  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin. Diabetes 27: 4-16 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Spectr. 22: 6-17 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203 [Abstract] [Full Text]  
• Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association . Diabetes Care 32: 187-192 [Full Text]  
• Sheehy, A. M., Coursin, D. B., Gabbay, R. A. (2009). Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. Mayo Clin Proc. 84: 38-42 [Full Text]  
• Inge, T. H., Miyano, G., Bean, J., Helmrath, M., Courcoulas, A., Harmon, C. M., Chen, M. K., Wilson, K., Daniels, S. R., Garcia, V. F., Brandt, M. L., Dolan, L. M. (2009). Reversal of Type 2 Diabetes Mellitus and Improvements in Cardiovascular Risk Factors After Surgical Weight Loss in Adolescents. Pediatrics 123: 214-222 [Abstract] [Full Text]  
• Laczy, B., Hill, B. G., Wang, K., Paterson, A. J., White, C. R., Xing, D., Chen, Y.-F., Darley-Usmar, V., Oparil, S., Chatham, J. C. (2009). Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 296: H13-H28 [Abstract] [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Cryer, P. E. (2008). The Barrier of Hypoglycemia in Diabetes. Diabetes 57: 3169-3176 [Full Text]  
• Diabetes Control and Complications Trial/Epidemiol, (2008). Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus: 10 Years After the Diabetes Control and Complications Trial. Arch Ophthalmol 126: 1707-1715 [Abstract] [Full Text]  
• Yang, X., Ko, G. T.C., So, W. Y., Ma, R. C.W., Kong, A. P.S., Lam, C. W.K., Ho, C. S., Chow, C.-C., Tong, P. C.Y., Chan, J. C.N. (2008). Additive Interaction of Hyperglycemia and Albuminuria on Risk of Ischemic Stroke in Type 2 Diabetes: Hong Kong Diabetes Registry. Diabetes Care 31: 2294-2300 [Abstract] [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Goodarzi, M. O., Psaty, B. M. (2008). Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes: Treating the Wrong Surrogate End Point?. JAMA 300: 2051-2053 [Full Text]  
• Shani, M., Taylor, T. R., Vinker, S., Lustman, A., Erez, R., Elhayany, A., Lahad, A. (2008). Characteristics of Diabetics with Poor Glycemic Control Who Achieve Good Control. J Am Board Fam Med 21: 490-496 [Abstract] [Full Text]  
• Kilpatrick, E. S., Rigby, A. S., Atkin, S. L. (2008). A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes: Data from the Diabetes Control and Complications Trial. Diabetes Care 31: 2198-2202 [Abstract] [Full Text]  
• Giorda, C. B., Avogaro, A., Maggini, M., Lombardo, F., Mannucci, E., Turco, S., Alegiani, S. S., Raschetti, R., Velussi, M., Ferrannini, E., for the Diabetes and Informatics Study Group, (2008). Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes: Epidemiology and risk factors. Diabetes Care 31: 2154-2159 [Abstract] [Full Text]  
• Dasu, M. R., Devaraj, S., Zhao, L., Hwang, D. H., Jialal, I. (2008). High Glucose Induces Toll-Like Receptor Expression in Human Monocytes: Mechanism of Activation. Diabetes 57: 3090-3098 [Abstract] [Full Text]  
• Nathan, D. M. (2008). Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There. Arch Intern Med 168: 2064-2066 [Full Text]  
• Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., Brancati, F. L. (2008). Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review. Arch Intern Med 168: 2070-2080 [Abstract] [Full Text]  
• Majumdar, S., Barrett, E. (2008). Newer Insulins in Search of a Niche. ANN INTERN MED 149: 586-588 [Full Text]  
• Home, P. (2008). Tight control of blood glucose and cardiovascular disease. BMJ 337: a2105-a2105 [Full Text]  
• Chalmers, J., Cooper, M. E. (2008). UKPDS and the Legacy Effect. NEJM 359: 1618-1620 [Full Text]  
• The Juvenile Diabetes Research Foundation Continuo, (2008). Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. NEJM 359: 1464-1476 [Abstract] [Full Text]  
• Kahn, S. E., Cefalu, W. T. (2008). Glucose Control, Macro- and Microvascular Disease, and the Food and Drug Administration: Let's Keep Our Eye on the Ball. J. Clin. Endocrinol. Metab. 93: 3727-3729 [Full Text]  
• Maile, L. A., Capps, B. E., Miller, E. C., Aday, A. W., Clemmons, D. R. (2008). Integrin-Associated Protein Association With Src Homology 2 Domain Containing Tyrosine Phosphatase Substrate 1 Regulates IGF-I Signaling In Vivo. Diabetes 57: 2637-2643 [Abstract] [Full Text]  
• Pommer, W. (2008). Prevalence of nephropathy in the German diabetes population--Is early referral to nephrological care a realistic demand today?. NDT Plus 1: iv2-iv5 [Abstract] [Full Text]  
• El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., Brownlee, M. (2008). Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. JEM 205: 2409-2417 [Abstract] [Full Text]  
• Reddy, M. A., Villeneuve, L. M., Wang, M., Lanting, L., Natarajan, R. (2008). Role of the Lysine-Specific Demethylase 1 in the Proinflammatory Phenotype of Vascular Smooth Muscle Cells of Diabetic Mice. Circ. Res. 103: 615-623 [Abstract] [Full Text]  
• Bailey, C. J, Day, C. (2008). Glycaemic memory. British Journal of Diabetes & Vascular Disease 8: 242-247 [Abstract]  
• Kilpatrick, E S (2008). Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus. J. Clin. Pathol. 61: 977-982 [Abstract] [Full Text]  
• Berg, A H, Sacks, D B (2008). Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony. J. Clin. Pathol. 61: 983-987 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Approaches to Treatment of Type 2 Diabetes. Diabetes Care 31: 1697-1703 [Full Text]  
• Yamagishi, S.-i. (2008). Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. Eur Heart J 29: 1922-1922 [Full Text]  
• Duke, D. C., Geffken, G. R., Lewin, A. B., Williams, L. B., Storch, E. A., Silverstein, J. H. (2008). Glycemic Control in Youth with Type 1 Diabetes: Family Predictors and Mediators. J Pediatr Psychol 33: 719-727 [Abstract] [Full Text]  
• Fowler, M. J. (2008). Diabetes Devices. Clin. Diabetes 26: 130-133 [Full Text]  
• Chamberlain, J. J., Small, D. (2008). Successful Use of a Single Subcutaneous Continuous Glucose Monitor Sensor for 28 Days in a Patient with Type 1 Diabetes. Clin. Diabetes 26: 138-139 [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Saudek, C. D., Herman, W. H., Sacks, D. B., Bergenstal, R. M., Edelman, D., Davidson, M. B. (2008). A New Look at Screening and Diagnosing Diabetes Mellitus. J. Clin. Endocrinol. Metab. 93: 2447-2453 [Abstract] [Full Text]  
• Huang, E. S., Zhang, Q., Gandra, N., Chin, M. H., Meltzer, D. O. (2008). The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis. ANN INTERN MED 149: 11-19 [Abstract] [Full Text]  
• Villeneuve, L. M., Reddy, M. A., Lanting, L. L., Wang, M., Meng, L., Natarajan, R. (2008). Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. USA 105: 9047-9052 [Abstract] [Full Text]  
• Dluhy, R. G., McMahon, G. T. (2008). Intensive Glycemic Control in the ACCORD and ADVANCE Trials. NEJM 358: 2630-2633 [Full Text]  
• Mozaffarian, D., Wilson, P. W.F., Kannel, W. B. (2008). Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease. Circulation 117: 3031-3038 [Full Text]  
• Norris, S. L., Kansagara, D., Bougatsos, C., Fu, R. (2008). Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 148: 855-868 [Abstract] [Full Text]  
• Kodl, C. T., Seaquist, E. R. (2008). Cognitive Dysfunction and Diabetes Mellitus. Endocr. Rev. 29: 494-511 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]  
• Schroeder, S. A., Tayek, J. A., Gaede, P., Parving, H.-H., Pedersen, O. (2008). Multifactorial Intervention and Mortality in Type 2 Diabetes. NEJM 358: 2292-2293 [Full Text]